Activity of thalidomide in AIDS-related Kaposi's sarcoma

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2593-2602

  Little, Richard F ^a   Wyvill, Kathleen M ^a   Pluda, James M ^a   Welles, Lauri ^a   Marshall, Vickie ^a   Figg, William D ^a   Newcomb, Fonda M ^a   Tosato, Giovanna ^a   Feigal, Ellen ^a   Steinberg, Seth M ^a   Whitby, Denise ^a   Goedert, James J ^a   Yarchoan, Robert ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADULT; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; NEUROPATHY; PRIORITY JOURNAL; SOMNOLENCE; TUMOR VASCULARIZATION;

EID: 0033916672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2593     Document Type: Article

References (67)

1. Friedman-Kien AE: Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol 5:468-471, 1981
2. Dezube BJ: Clinical presentation and natural history of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am 10:1023-1029, 1996
3. Garay SM, Belenko M, Fazzini E, et al: Pulmonary manifestations of Kaposi's sarcoma. Chest 91:39-43, 1987
4. Volm MD, von Roenn JH: Treatment strategies for epidemic Kaposi's sarcoma. Curr Opin Oncol 7:429-436, 1995
5. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997
6. Harrison M, Tomlinson D, Stewart S: Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920, 1995
7. Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364, 1996
8. Saville MW, Lietzau J, Pluda JM, et al: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346:26-28, 1995
9. Gill P, Scadden D, Groopman J, et al: Low dose paclitaxel (Taxol) is highly effective in the treatment of patients with advanced AIDS-related Kaposi's sarcoma. J AIDS, Abstracts of the First National AIDS Malignancy Conference 14:A35, 1997 (abstr 77)
10. Rutgers JL, Wieczorek R, Bonetti F, et al: The expression of endothelial cell surface antigens by AIDS-associated Kaposi's sarcoma: Evidence for a vascular endothelial cell origin. Am J Pathol 122:493-499, 1986
11. Rabkin CS, Janz S, Lash A, et al: Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 336:988-993, 1997
12. Ensoli B, Nakamura S, Salahuddin SZ, et al: AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243:223-226, 1989
13. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al: AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A 87:4068-4072, 1990
14. Nakamura S, Murakami-Mori K, Rao N, et al: Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. J Immunol 158:4992-5001, 1997
15. Samaniego F, Markham PD, Gendelman R, et al: Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 152:1433-1443, 1998
16. Ensoli B, Gendelman R, Markham P, et al: Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371:674-680, 1994
17. Friedlander M, Brooks PC, Shaffer RW, et al: Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502, 1995
18. Chang Y, Cesarman E, Pessin M, et al: Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994
19. Cesarman E, Chang Y, Moore PS, et al: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191, 1995
20. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332:1181-1185, 1995
21. Boshoff C, Schulz TF, Kennedy MM, et al: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1:1274-1278, 1995
22. Moore PS, Boshoff C, Weiss RA, et al: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-1744, 1996
23. Bais C, Santomasso B, Coso O, et al: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89, 1998
24. Nicholas J, Ruvolo VR, Burns WH, et al: Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 3:287-292, 1997
25. Boshoff C, Endo Y, Collins PD, et al: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278:290-294, 1997
26. D'Amato R, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
27. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834, 1998
28. Jacobson JM, Greenspan JS, Spritzler J, et al: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336:1487-1493, 1997
29. Wittes RE: Common toxicity criteria for cancer clinical trials, Version 1.0, in MacDonald JS, Haller DG, Mayer RJ (eds): Manual of Oncologic Therapeutics (ed3). Philadelphia, PA, Lippincott, 1995, pp 445-448
30. Krown SE, Testa MA, Huang J: AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification: AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 15:3085-3092, 1997
31. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 7:1201-1207, 1989
32. Welles L, Saville MW, Lietzau J, et al: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 16:1112-1121, 1998
33. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244, 1999
34. Marshall VA, Miley W, Drummond J, et al: Real time detection and quantitation of human herpes virus 8 (hhv-8) in human cells using PCR and taqman chemistry. 1998 Meeting of the Institute of Human Virology. Baltimore, MD. 1998, pp 99 (abstr 271)
35. Simmons BR, Lush RM, Figg WD: A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Anal Chim Acta 339:91-97, 1997
36. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
37. Atkinson EN, Brown BW: Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 41:741-744, 1985
38. Cattelan AM, Calabro ML, Aversa SML, et al: HAART treatment for AIDS-related KS? 1999 Meeting of the Institute of Human Virology. Baltimore, MD, Lippincott Williams & Wilkins, 1999 pp 200 (abstr 121)
39. Sasaki T, Maita E: Increased bFGF level in the serum of patients with phenytoin-induced gingival overgrowth. J Clin Periodontol 25:42-47, 1998
40. Kikuchi K, Kubo M, Kadono T, et al: Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049-1051, 1998
41. Jones PD, Shelley L, Wakefield D: Tumor necrosis factor-alpha in advanced HIV infection in the absence of AIDS-related secondary infections. J Acquir Immune Defic Syndr 5:1266-1271, 1992
42. Honda M, Kitamura K, Mizutani Y, et al: Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases. J Immunol 145:4059-4064, 1990
43. Pluda JM, Shay LE, Foli A, et al: Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 85:1585-1592, 1993
44. Schwartsmann G, Sprinz E, Kalakun L, et al: Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumori 82:360-363, 1996
45. Pluda JM, Wyvill K, Lietzau J, et al: A phase I trial of TNP-470 (AGM-1470) administered to patients with HIV-associated Kaposi's sarcoma (KS). Abstracts of the First National Conference on Human Retroviruses and Related Infections. Washington, DC, 1993, pp 61
46. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al: Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study - AIDS Clinical Trial Group No 215 Team. J Clin Oncol 16:1444-1449, 1998
47. Stewart JSW, Jablonowksi H, Goebel FD, et al: A randomized comparative trial of Doxil versus bleomycin and vincristine (BV) in the treatment of AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 55a, 1997 (abstr 190)
48. Safai B, Johnson KG, Myskowski PL, et al: The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103:744-750, 1985
49. Mitsuyasu RT, Taylor JMG, Glaspy J, et al: Heterogeneity of epidemic Kaposi's sarcoma: Implications for therapy. Cancer 57:1657-1661, 1986
50. Bailey J, Pluda JM, Foli A, et al: Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with Interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 13:1966-1974, 1995
51. Aboulafia DM: Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 73:439-443, 1998
52. Santambrogio S, Ridolfo AL, Tosca N, et al: Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated Kaposi's sarcoma (KS). 12th World AIDS Conference. Geneva, Switzerland, 1998, pp 317 (abstr 617/22275)
53. Pearson JM, Vedagiri M: Treatment of moderately severe erythema nodosum leprosum with thalidomide: A double-blind controlled trial. Lepr Rev 40:111-116, 1969
54. Alexander LN, Wilcox CM: A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 13:301-304, 1997
55. Moreira AL, Corral LG, Ye W, et al: Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 13:857-863, 1997
56. Sampaio EP, Sarno EN, Galilly R, et al: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703, 1991
57. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90:5974-5978, 1993
58. McHugh SM, Rifkin IR, Deighton J, et al: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160-167, 1995
59. Haslett PA, Klausner JD, Makonkawkeyoon S, et al: Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retrovirases 15:1169-1179, 1999
60. Samaniego F, Markham PD, Gendelman R, et al: Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 158:1887-1894, 1997
61. Ensoli B, Barillari G, Salanuddin SZ, et al: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345:84-86, 1990
62. Fife K, Howard MR, Gracie F, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 9:751-755, 1998
63. Fine HA, Loeffler JS, Kyritsis A, et al: A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc Am Soc Clin Oncol 16:385a, 1997 (abstr 1372)
64. Figg WD, Bergan R, Brawley O, et al: Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 16:333a, 1997 (abstr 1189)
65. Figg WD, Raje S, Bauer KS, et al: Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 88:121-125, 1999
66. Soler RA, Howard M, Brink NS, et al: Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 23:501-505, 1996
67. Politi P, Reboredo G, Losso M, et al: Phase I trial of thalidomide (T) in AIDS-related Kaposi sarcoma (KS). Proc Am Soc Clin Oncol 17:41a, 1998 (abstr 161)